Epcoritamab
Post-Transplant Lymphoproliferative Disease
Explore 17 assets in Post-Transplant Lymphoproliferative Disease →Floatz Rating
B58/100
Confidence
Indicative
Sponsor
Northwestern University
Modality
monoclonal_antibody
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
45Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT06723457CT.gov Epcoritamab and Lenalidomide in Treating Patients With Refractory or Relapsed Immunodeficiency-Related Large B-Cell Lymphoma | — | Active Not Recruiting | — | — | — |
NCT06672705CT.gov Epcoritamab for the Treatment of Relapsed or Refractory Post Transplant Lymphoproliferative Disorders | — | Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Post-Transplant Lymphoproliferative Disease
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Epcoritamab (this asset) | Northwestern University | P2 | B · 58 |
| Cyclophosphamide | Washington University School of Medicine | P2 | BBB |
| Rituximab | Jennifer Amengual | P2 | BB |
| Fludarabine | City of Hope Medical Center | P2 | BB |
| Cyclosporin A | National Cancer Institute (NCI) | P2 | BB |
| Lenalidomide | Northwestern University | P2 | B |
| Nivestim | Baylor College of Medicine | P2 | B |
| Methotrexate | National Cancer Institute (NCI) | P2 | B |
| Tacrolimus | University of Medicine and Dentistry of New Jersey | P2 | B |
+39 more in the Post-Transplant Lymphoproliferative Disease cohort
Other indications for Epcoritamab
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | — | P2 | BB · 65 |
| Diffuse Large B-Cell Lymphoma | — | P3 | BB · 65 |
| Primary Central Nervous System Lymphoma | — | P2 | B · 60 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Epcoritamab in Post-Transplant Lymphoproliferative Disease. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 9, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/epcoritamab-post-transplant-lymphoproliferative-disease
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →